Sarx

Greek: Σαρξ

*noun*: muscle, tissue
Meet our Launch Team

Mark Platt
Chief Executive Officer
Recombinetics, Inc.

Themis Kyriakides
Professor of Pathology and Biomedical Engineering
Yale University

David Lewin
Director of Business Development
Yale University

Dmytro Ustianenko
Blavatnik Fellow
Yale University
Sarxion Biologics is a unique partnership

- 6-year collaboration
- Tested and productive partnership

- Joint NIH-SBIR award ($400,000 in funding)
- Allowed and Pending Patent Applications

- Complimentary scientific expertise
- Proprietary animal genetic editing platform
- Industry leading animal husbandry capability
Hernia repair – the most common abdominal surgical procedure

1M hernia repairs in the US annually

Over 12% of population will experience inguinal hernia in the lifetime

$10B/annually
Commonly used materials in standard of care

**Synthetics**

- ULTRAPRO® Macroporous

**Biologics**

- Strattice RTM
Biologic hernia patch limitations

- High Complication Rates
- 14%-59% recurrence rate
- Compliance mismatch
- Poor Integration
- Higher cost

Core Weakness: Poor Tissue Integration
Extracellular matrix – an essential component of biologic hernia patch

Extracellular matrix (ECM):

- Main component of the Biological Hernia Patch
- Consists of interconnecting protein fibers
- Guides tissue remodeling and rate of wound healing
Sarxion Biologics ECM material has improved integration and healing

- Knock out of TSP2 – confounding matrix protein
- Increased compatibility with host tissue
- Extensively characterized using mouse and porcine model
Sarxion Biologics has the superior solution for hernia repair

- Faster and increased cell migration
- Increased blood vessel formation
- Reduced clotting
- Excellent biomechanical compliance
- Seamless integration with the host tissue
Sarxion Biologics is a platform company

- Hernia patches $300K
- Hydrogel $250K
- Vascular grafts $200K
- Plastic surgery $200K
- Heart valves $50K

Total potential value/animal: $1M

Sarxion Biologics is a multi-indication company
Our roadmap, accomplishments, and goals - Value to patients as soon as possible

1. Build strong IP portfolio
2. Develop TSP2-KO porcine model
3. Establish strategic partnership
4. Apply for 510k approval
5. Commercialize hernia patch
## Sarxion Biologics timeline to the market

<table>
<thead>
<tr>
<th>Milestones</th>
<th>Q1-2 2022</th>
<th>Q2-3 2022</th>
<th>Q1-2 2023</th>
<th>Q3-Q4 2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characterize Pigs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-510k FDA steps</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Validation though CRO</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>510k FDA meeting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large animal studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>510k filing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Series A/Partnering</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commercialization - Hernia Patch</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Raising $5M ➔ 510k Filing**
Contact information:  
Mark Platt  
mark.platt@recombinetics.com
ECM-modified decellularized rat small diameter vascular grafts

Unmodified

WT ECM

TSP2 KO ECM